Author Archives: donttradeourlivesaway

New development in the COPD drug Indaceterol

The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at … Continue reading

Posted in access to medicines, Drug Pricing, Revocation | Tagged , , | Leave a comment

Trading away democracy. How CETA’s investor protection rules threaten the public good in Canada and the EU

Source: Corporate Europe Observatory November 19th,2014 The first in-depth analysis of the investment provisions of the Canadian-EU free trade agreement (CETA) has found that both the EU and Canada will be exposing themselves to greater future government policy constrain, and … Continue reading

Posted in FTAs, investor state dispute | Tagged | Leave a comment

Update on Letter to Chief Justice of India by Campaign for Affordable Trastuzumab

Subsequent to the letter to Chief Justice of India by Campaign for Affordable Trastuzumab stating concerns regarding IP Owners Association (IPOA) with India judiciary ,  we have heard from the credible sources that IPOA’s meeting with IPAB and Delhi High Court … Continue reading

Posted in Campaign for Affordable Trastuzumab, Conflict of Interest | Leave a comment

Corruption tars drug industry drive to improve access for poor; GlaxoSmithKline retains top spot

Source: Economic Times November 17,2014 LONDON: The world’s top drugmakers have improved access to medicines in developing countries, according to a report on Monday, but their good work is undermined by a sorry record of unethical behaviour. The Access to … Continue reading

Posted in access to medicines, patent | Tagged , , , | Leave a comment

Another big fat lie on R&D Cost for developing a new drug

The Tufts Center for the Study of Drug Development, non profit group has released a study giving R&D cost of $ 2.558 million for developing a new drug.Read their press release below. While they claim to be independent academic organisation, … Continue reading

Posted in access to medicines, Drug Pricing, R&D | Leave a comment

Corruption tars drug industry drive to improve access for poor

Source: Reuters November 16,2014  The world’s top drugmakers have improved access to medicines in developing countries, according to a report on Monday, but their good work is undermined by a sorry record of unethical behavior. The Access to Medicines Index, … Continue reading

Posted in access to medicines | Tagged , , , , , | Leave a comment

R&D cost estimates – MSF response to Tufts CSDD study on cost to develop a new drug

Source: MSF Access Campaign November 18,2014 Quote: “The pharmaceutical industry-supported Tufts Center for the Study of Drug Development claims it costs US$2.56 billion to develop a new drug today; but if you believe that, you probably also believe the earth … Continue reading

Posted in access to medicines, Drug Pricing, R&D | Leave a comment